Senior Director, In Vivo Pharmacology at Abata Therapeutics

San Carlos, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

PhD in Molecular & Cell Biology, Genetics, Biochemistry, Immunology, Physiology or related areas
Minimum 15 years of experience designing, executing, and overseeing in vivo pharmacology studies to support projects in the pharmaceutical or biotech industry, with emphasis on in vivo models of immunology and inflammation in the gut, skin, respiratory organs, and autoimmune diseases
Minimum 10 years of experience managing teams and representing Pharmacology on cross-functional teams
Experience in generating and managing pre-IND reports (strongly preferred)
Prior experience with biologics drug discovery and development (preferred)
Previous experience working in fast-paced start-up environments (preferred)
Strong technical expertise in study design methodologies and a wide range of in vivo autoimmune and inflammatory disease models
Strategic thinker with ability to analyze possibilities, evaluate benefits/risks, and develop mitigation strategies and solutions
Strong leadership and program management skills, including experience building, leading, and developing strong and collaborative scientific teams
Strong communication skills, with ability to effectively collaborate with cross-functional teams and external partners
Demonstrated ability to stay updated with latest advancements and trends in in vivo research
Proactive and able to work effectively on multiple projects in a fast-paced, dynamic environment
Strong written and verbal communication skills

Responsibilities

Provide leadership in preclinical pharmacological program development from target validation to successful regulatory filings for mono- and multispecific biologics
Manage all in-vivo pharmacology studies, including design, implementation, conduct, and reporting
Facilitate the conceptualization and development of innovative research strategies and plans for preclinical studies aligned with the company's therapeutic portfolio and goals
Identify, assess, and oversee various contract research organizations (CROs) to complement internal capabilities and generate critical pharmacokinetic, pharmacodynamic, and efficacy data
Foster effective collaboration and communication with internal teams, external partners, and key stakeholders to ensure alignment of research objectives and facilitate knowledge sharing
Perform independent research within the field of study to provide leadership to advance optimization of in vivo research methodologies, technologies, and industry trends
Develop and present Pharmacology strategy, plans, and data at project team meetings and to management to support project objectives
Support the filing of regulatory documents, including preparation of final study reports and IND (or related) documents
Contribute to a team culture that promotes collaboration, open communication, career development, excellence, ownership, curiosity, and inclusion
Lead a small but motivated in vivo team
Collaborate with cross-functional partners to manage resource allocations to enable portfolio progression

Skills

In Vivo Pharmacology

Preclinical Studies

Pharmacokinetics

Pharmacodynamics

Efficacy Studies

CRO Management

Target Validation

Translational Biology

Regulatory Filings

FDA IND

Biologics

Multispecific Antibodies

Immunology

Inflammation

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free